Compare Intuitive Surgical, Inc. (ISRG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Natera Inc. Common Stock — how do they compare? Intuitive Surgical, Inc. trades at $422.44 (market cap $148.46B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Intuitive Surgical, Inc. is far larger — about 2.6× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Natera Inc. Common Stock for 0 Days on average.
| ISRG | NTRA | |
|---|---|---|
Market Cap | $148.46B | $57.03B |
Volume | 1,914,576 | 1,131,157 |
Sector | Health | Health |
52-Week High | $592.85 | $425.64 |
52-Week Low | $332.02 | $179.42 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $143.25B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $422.06, down 1.3% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth from $6.2B in 2022 to $10.1B in 2025. The stock shows bullish technical signals with support at $414 and resistance at $431, while analyst consensus remains strongly positive with a $480.78 price target. Recent expansion into India and Japan helps offset China weakness, with da Vinci 5 upgrades driving recurring revenue streams.
ISRG presents a compelling growth opportunity with market leadership in robotic surgery and expanding international presence, though elevated valuation multiples (P/E 48.4) and competitive pressures warrant caution. The 70% buy rating from analysts suggests significant upside potential, but investors should monitor procedure growth rates and macroeconomic pressures affecting healthcare spending.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
